Drug intelligence / Profile preview

DIM-3,5

Development stage
Preclinical
Lead developer
Texas A&M University
Modality
Small Molecules
01

Overview

DIM-3,5 refers to a series of 1,1-bis(3′-indolyl)-1-(3,5-disubstitutedphenyl)methane analogs that act as potent anticancer agents. These compounds function as dual inverse agonists of the orphan nuclear receptors NR4A1 (Nur77) and NR4A2 (Nurr1). In glioblastoma (GBM) research, DIM-3,5 analogs have demonstrated the ability to downregulate the expression of O6-methylguanine-DNA methyltransferase (MGMT), a key enzyme associated with resistance to the alkylating chemotherapy temozolomide (TMZ). By inhibiting the transcriptional regulation of MGMT mediated by NR4A1, NR4A2, and Sp1, these analogs reduce MGMT mRNA and protein levels, potentially sensitizing resistant glioblastoma phenotypes to standard-of-care treatment.

Other names
1,1-bis(3′-indolyl)-1-(3,5-disubstitutedphenyl)methane analogsbis-indole derived dual NR4A1/2 inverse agonists
02

Targets

NR4A2 (Nuclear receptor subfamily 4 group A member 2)NR4A1 (Nuclear receptor subfamily 4 group A member 1)

Beyond the preview

Go deeper on DIM-3,5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIM-3,5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call